Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age

D. E. Reece, C. Bredeson, W. S. Pérez, S. Jagannath, M. J. Zhang, K. K. Ballen, G. J. Elfenbein, C. O. Freytes, R. P. Gale, M. A. Gertz, J. Gibson, S. A. Giralt, A. Keating, R. A. Kyle, D. Maharaj, D. Marcellus, P. L. McCarthy, G. A. Milone, Stephen D Nimer, S. PavlovskyL. B. To, D. J. Weisdorf, P. H. Wiernik, J. R. Wingard, D. H. Vesole

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

The role of autologous stem cell transplantation (AuSCT) in older multiple myeloma patients is unclear. Using data from the Autologous Blood and Marrow Transplant Registry, we compared the outcome of 110 patients ≥the age of 60 (median 63; range 60-73) years, undergoing AuSCT with that of 382 patients <60 (median 52; range 30-59) years. The two groups were similar except that older patients had a higher β2-microglobulin level at diagnosis (P=0.016) and fewer had lytic lesions (P=0.007). Day 100 mortality was 6% (95% confidence interval 4-9) and 1-year treatment-related mortality (TRM) was 9% (6-13) in patients <60 years, compared with 5% (2-10) and 8% (4-14), respectively, in patients ≥60 years. The relapse rate, progression-free survival (PFS) and overall survival (OS) in the two groups were also similar. Multivariate analysis of all patients identified only an interval from diagnosis to AuSCT > 12 months and the use of two prior chemotherapy regimens within 6 months of AuSCT as adverse prognostic factors. Our results indicate that AuSCT can be safely performed in selected older patients: the best results were observed in patients undergoing AuSCT relatively early in their disease course.

Original languageEnglish
Pages (from-to)1135-1143
Number of pages9
JournalBone Marrow Transplantation
Volume32
Issue number12
DOIs
StatePublished - Dec 1 2003
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Multiple Myeloma
Registries
Bone Marrow
Transplants
Drug Therapy

Keywords

  • Autologous transplantation
  • Multiple myeloma
  • Older patients

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Reece, D. E., Bredeson, C., Pérez, W. S., Jagannath, S., Zhang, M. J., Ballen, K. K., ... Vesole, D. H. (2003). Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age. Bone Marrow Transplantation, 32(12), 1135-1143. https://doi.org/10.1038/sj.bmt.1704288

Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age. / Reece, D. E.; Bredeson, C.; Pérez, W. S.; Jagannath, S.; Zhang, M. J.; Ballen, K. K.; Elfenbein, G. J.; Freytes, C. O.; Gale, R. P.; Gertz, M. A.; Gibson, J.; Giralt, S. A.; Keating, A.; Kyle, R. A.; Maharaj, D.; Marcellus, D.; McCarthy, P. L.; Milone, G. A.; Nimer, Stephen D; Pavlovsky, S.; To, L. B.; Weisdorf, D. J.; Wiernik, P. H.; Wingard, J. R.; Vesole, D. H.

In: Bone Marrow Transplantation, Vol. 32, No. 12, 01.12.2003, p. 1135-1143.

Research output: Contribution to journalArticle

Reece, DE, Bredeson, C, Pérez, WS, Jagannath, S, Zhang, MJ, Ballen, KK, Elfenbein, GJ, Freytes, CO, Gale, RP, Gertz, MA, Gibson, J, Giralt, SA, Keating, A, Kyle, RA, Maharaj, D, Marcellus, D, McCarthy, PL, Milone, GA, Nimer, SD, Pavlovsky, S, To, LB, Weisdorf, DJ, Wiernik, PH, Wingard, JR & Vesole, DH 2003, 'Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age', Bone Marrow Transplantation, vol. 32, no. 12, pp. 1135-1143. https://doi.org/10.1038/sj.bmt.1704288
Reece DE, Bredeson C, Pérez WS, Jagannath S, Zhang MJ, Ballen KK et al. Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age. Bone Marrow Transplantation. 2003 Dec 1;32(12):1135-1143. https://doi.org/10.1038/sj.bmt.1704288
Reece, D. E. ; Bredeson, C. ; Pérez, W. S. ; Jagannath, S. ; Zhang, M. J. ; Ballen, K. K. ; Elfenbein, G. J. ; Freytes, C. O. ; Gale, R. P. ; Gertz, M. A. ; Gibson, J. ; Giralt, S. A. ; Keating, A. ; Kyle, R. A. ; Maharaj, D. ; Marcellus, D. ; McCarthy, P. L. ; Milone, G. A. ; Nimer, Stephen D ; Pavlovsky, S. ; To, L. B. ; Weisdorf, D. J. ; Wiernik, P. H. ; Wingard, J. R. ; Vesole, D. H. / Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age. In: Bone Marrow Transplantation. 2003 ; Vol. 32, No. 12. pp. 1135-1143.
@article{940833962218481f8d30013b4dc173c9,
title = "Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age",
abstract = "The role of autologous stem cell transplantation (AuSCT) in older multiple myeloma patients is unclear. Using data from the Autologous Blood and Marrow Transplant Registry, we compared the outcome of 110 patients ≥the age of 60 (median 63; range 60-73) years, undergoing AuSCT with that of 382 patients <60 (median 52; range 30-59) years. The two groups were similar except that older patients had a higher β2-microglobulin level at diagnosis (P=0.016) and fewer had lytic lesions (P=0.007). Day 100 mortality was 6{\%} (95{\%} confidence interval 4-9) and 1-year treatment-related mortality (TRM) was 9{\%} (6-13) in patients <60 years, compared with 5{\%} (2-10) and 8{\%} (4-14), respectively, in patients ≥60 years. The relapse rate, progression-free survival (PFS) and overall survival (OS) in the two groups were also similar. Multivariate analysis of all patients identified only an interval from diagnosis to AuSCT > 12 months and the use of two prior chemotherapy regimens within 6 months of AuSCT as adverse prognostic factors. Our results indicate that AuSCT can be safely performed in selected older patients: the best results were observed in patients undergoing AuSCT relatively early in their disease course.",
keywords = "Autologous transplantation, Multiple myeloma, Older patients",
author = "Reece, {D. E.} and C. Bredeson and P{\'e}rez, {W. S.} and S. Jagannath and Zhang, {M. J.} and Ballen, {K. K.} and Elfenbein, {G. J.} and Freytes, {C. O.} and Gale, {R. P.} and Gertz, {M. A.} and J. Gibson and Giralt, {S. A.} and A. Keating and Kyle, {R. A.} and D. Maharaj and D. Marcellus and McCarthy, {P. L.} and Milone, {G. A.} and Nimer, {Stephen D} and S. Pavlovsky and To, {L. B.} and Weisdorf, {D. J.} and Wiernik, {P. H.} and Wingard, {J. R.} and Vesole, {D. H.}",
year = "2003",
month = "12",
day = "1",
doi = "10.1038/sj.bmt.1704288",
language = "English",
volume = "32",
pages = "1135--1143",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age

AU - Reece, D. E.

AU - Bredeson, C.

AU - Pérez, W. S.

AU - Jagannath, S.

AU - Zhang, M. J.

AU - Ballen, K. K.

AU - Elfenbein, G. J.

AU - Freytes, C. O.

AU - Gale, R. P.

AU - Gertz, M. A.

AU - Gibson, J.

AU - Giralt, S. A.

AU - Keating, A.

AU - Kyle, R. A.

AU - Maharaj, D.

AU - Marcellus, D.

AU - McCarthy, P. L.

AU - Milone, G. A.

AU - Nimer, Stephen D

AU - Pavlovsky, S.

AU - To, L. B.

AU - Weisdorf, D. J.

AU - Wiernik, P. H.

AU - Wingard, J. R.

AU - Vesole, D. H.

PY - 2003/12/1

Y1 - 2003/12/1

N2 - The role of autologous stem cell transplantation (AuSCT) in older multiple myeloma patients is unclear. Using data from the Autologous Blood and Marrow Transplant Registry, we compared the outcome of 110 patients ≥the age of 60 (median 63; range 60-73) years, undergoing AuSCT with that of 382 patients <60 (median 52; range 30-59) years. The two groups were similar except that older patients had a higher β2-microglobulin level at diagnosis (P=0.016) and fewer had lytic lesions (P=0.007). Day 100 mortality was 6% (95% confidence interval 4-9) and 1-year treatment-related mortality (TRM) was 9% (6-13) in patients <60 years, compared with 5% (2-10) and 8% (4-14), respectively, in patients ≥60 years. The relapse rate, progression-free survival (PFS) and overall survival (OS) in the two groups were also similar. Multivariate analysis of all patients identified only an interval from diagnosis to AuSCT > 12 months and the use of two prior chemotherapy regimens within 6 months of AuSCT as adverse prognostic factors. Our results indicate that AuSCT can be safely performed in selected older patients: the best results were observed in patients undergoing AuSCT relatively early in their disease course.

AB - The role of autologous stem cell transplantation (AuSCT) in older multiple myeloma patients is unclear. Using data from the Autologous Blood and Marrow Transplant Registry, we compared the outcome of 110 patients ≥the age of 60 (median 63; range 60-73) years, undergoing AuSCT with that of 382 patients <60 (median 52; range 30-59) years. The two groups were similar except that older patients had a higher β2-microglobulin level at diagnosis (P=0.016) and fewer had lytic lesions (P=0.007). Day 100 mortality was 6% (95% confidence interval 4-9) and 1-year treatment-related mortality (TRM) was 9% (6-13) in patients <60 years, compared with 5% (2-10) and 8% (4-14), respectively, in patients ≥60 years. The relapse rate, progression-free survival (PFS) and overall survival (OS) in the two groups were also similar. Multivariate analysis of all patients identified only an interval from diagnosis to AuSCT > 12 months and the use of two prior chemotherapy regimens within 6 months of AuSCT as adverse prognostic factors. Our results indicate that AuSCT can be safely performed in selected older patients: the best results were observed in patients undergoing AuSCT relatively early in their disease course.

KW - Autologous transplantation

KW - Multiple myeloma

KW - Older patients

UR - http://www.scopus.com/inward/record.url?scp=0346496578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346496578&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704288

DO - 10.1038/sj.bmt.1704288

M3 - Article

C2 - 14647267

AN - SCOPUS:0346496578

VL - 32

SP - 1135

EP - 1143

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 12

ER -